NO20060400L - Sammensetninger for rensing og krystallisering av molekyler av interesse - Google Patents

Sammensetninger for rensing og krystallisering av molekyler av interesse

Info

Publication number
NO20060400L
NO20060400L NO20060400A NO20060400A NO20060400L NO 20060400 L NO20060400 L NO 20060400L NO 20060400 A NO20060400 A NO 20060400A NO 20060400 A NO20060400 A NO 20060400A NO 20060400 L NO20060400 L NO 20060400L
Authority
NO
Norway
Prior art keywords
crystallization
interest
compositions
purification
molecules
Prior art date
Application number
NO20060400A
Other languages
English (en)
Norwegian (no)
Inventor
Guy Patchornik
Original Assignee
Affisink Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affisink Biotechnology Ltd filed Critical Affisink Biotechnology Ltd
Publication of NO20060400L publication Critical patent/NO20060400L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20060400A 2003-07-24 2006-01-25 Sammensetninger for rensing og krystallisering av molekyler av interesse NO20060400L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL15708603A IL157086A0 (en) 2003-07-24 2003-07-24 Multivalent ligand complexes
PCT/IL2004/000669 WO2005010141A2 (en) 2003-07-24 2004-07-22 Compositions for purifying and crystallizing molecules of interest

Publications (1)

Publication Number Publication Date
NO20060400L true NO20060400L (no) 2006-03-27

Family

ID=32652285

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060400A NO20060400L (no) 2003-07-24 2006-01-25 Sammensetninger for rensing og krystallisering av molekyler av interesse

Country Status (13)

Country Link
US (1) US20060121519A1 (cg-RX-API-DMAC7.html)
EP (1) EP1648995A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007515384A (cg-RX-API-DMAC7.html)
KR (1) KR20060037337A (cg-RX-API-DMAC7.html)
CN (1) CN101415721A (cg-RX-API-DMAC7.html)
CA (1) CA2531492A1 (cg-RX-API-DMAC7.html)
IL (2) IL157086A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000944A (cg-RX-API-DMAC7.html)
NO (1) NO20060400L (cg-RX-API-DMAC7.html)
RU (1) RU2006105648A (cg-RX-API-DMAC7.html)
SG (1) SG145760A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005010141A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600315B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
WO2006085321A2 (en) * 2005-02-10 2006-08-17 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2009064425A1 (en) * 2007-11-13 2009-05-22 Rational Affinity Devices, L.L.C. Multistate affinity ligands for the separation and purification of antibodies, antibody fragments and conjugates of antibodies and antibody fragments
CA2708836A1 (en) * 2007-12-17 2009-06-25 Affisink Biotechnology Ltd. Methods for purifying or depleting molecules or cells of interest
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
KR101855714B1 (ko) 2010-03-05 2018-05-10 베링거 인겔하임 인터내셔날 게엠베하 항체의 선택적 농축
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
US10030224B2 (en) 2015-11-01 2018-07-24 Ariel-University Research And Development Company Ltd. Methods of analyzing cell membranes
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5215927A (en) * 1986-01-30 1993-06-01 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US20010008766A1 (en) * 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7198930B2 (en) * 2000-02-29 2007-04-03 Millennium Pharmaceuticals, Inc. Human protein kinase, phosphatase, and protease family members and uses thereof
JP5398945B2 (ja) * 2001-04-23 2014-01-29 マリンクロッド エルエルシー TcおよびRe標識放射活性グリコシル化オクトレオチド誘導体
US20040265921A1 (en) * 2003-06-30 2004-12-30 National University Of Singapore Intein-mediated attachment of ligands to proteins for immobilization onto a support
US7956165B2 (en) * 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest

Also Published As

Publication number Publication date
IL157086A0 (en) 2004-02-08
US20060121519A1 (en) 2006-06-08
JP2007515384A (ja) 2007-06-14
KR20060037337A (ko) 2006-05-03
WO2005010141A3 (en) 2009-03-26
SG145760A1 (en) 2008-09-29
ZA200600315B (en) 2007-04-25
EP1648995A4 (en) 2010-03-10
CN101415721A (zh) 2009-04-22
IL173107A0 (en) 2006-06-11
RU2006105648A (ru) 2006-07-27
MXPA06000944A (es) 2006-03-30
EP1648995A2 (en) 2006-04-26
WO2005010141A2 (en) 2005-02-03
CA2531492A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
Cauz‐Santos Beyond conservation: the landscape of chloroplast genome rearrangements in angiosperms
Sosa et al. Association between ancient bone preservation and DNA yield: a multidisciplinary approach
Lee et al. Complete chloroplast genomes of all six Hosta species occurring in Korea: molecular structures, comparative, and phylogenetic analyses
MX2008010481A (es) Compuestos que tienen afinado para el receptor f-ht6.
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
SG145760A1 (en) Compositions for purifying and crystallizing molecules of interest
WO2006069001A3 (en) Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
ATE305035T1 (de) Verfahren und verbindungen nützlich in der gezielten klonierung durch homologe rekombination
TW200740761A (en) Histone deacetylase inhibitors
BRPI0514694A (pt) produção de proteìna de fusão tnfr-ig
BRPI0906104B8 (pt) derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto
CA2369622A1 (en) Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
WO2006122319A3 (en) Histone deacetylase inhibitors
BRPI0412813A (pt) determinação da seqüência de um polinucleotìdeo
WO2010011680A8 (en) Discovery and utilization of sorghum genes (ma5/ma6)
NO20021686D0 (no) Fremgangsmåter for fremstilling av målemolekyler i et transgent dyr og rensing av målmolekylet
WO2003074660A3 (en) Modified chitin binding domain and uses thereof
Kratena et al. A unified approach to phytosiderophore natural products
Gordiyenko et al. Mass spectrometry defines the stoichiometry of ribosomal stalk complexes across the phylogenetic tree
WO2006085321A3 (en) Compositions and methods for purifying and crystallizing molecules of interest
EP1801208A4 (en) ANTI-A33 ANTIBODY
Liao et al. A novel polymeric silver (I) complex with a 2D brick structure
Thomas et al. Distamycin Analogues without Leading Amide at Their N‐Termini− Comparative Binding Properties to AT‐and GC‐Rich DNA Sequences
Pandit et al. A pmoA-based study reveals dominance of yet uncultured Type I methanotrophs in rhizospheres of an organically fertilized rice field in India

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application